Suppliers and packagers for dyrenium

dyrenium

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Advanz Pharma	DYRENIUM	triamterene	CAPSULE;ORAL	013174	NDA	Advanz Pharma (US) Corp.	59212-002-01	100 CAPSULE in 1 BOTTLE (59212-002-01)	1999-10-01
Advanz Pharma	DYRENIUM	triamterene	CAPSULE;ORAL	013174	NDA	Advanz Pharma (US) Corp.	59212-003-01	100 CAPSULE in 1 BOTTLE (59212-003-01)	1999-01-01
Advanz Pharma	DYRENIUM	triamterene	CAPSULE;ORAL	013174	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-831-02	100 CAPSULE in 1 BOTTLE (66993-831-02)	2019-08-13
Advanz Pharma	DYRENIUM	triamterene	CAPSULE;ORAL	013174	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-832-02	100 CAPSULE in 1 BOTTLE (66993-832-02)	2019-08-13

Suppliers for the Pharmaceutical Drug: DYRENIUM

Last updated: July 29, 2025

Introduction

In the competitive landscape of pharmaceuticals, identifying reliable suppliers for a drug like DYRENIUM is crucial for manufacturers, healthcare providers, and investors. DYRENIUM, a novel or proprietary medication (assuming based on its nomenclature), requires a precise supply chain to ensure quality, compliance, and cost-effectiveness. This article offers an in-depth review of existing suppliers, market dynamics, supply chain considerations, and strategic insights to inform procurement decisions.

Overview of DYRENIUM

While specific data on DYRENIUM might be limited as it appears to be a proprietary or investigational drug, it typifies the complex procurement processes characteristic of modern pharmaceuticals—especially biologics or specialty medicines. Its suppliers span raw material providers, active pharmaceutical ingredient (API) manufacturers, formulation entities, and packaging firms. Ensuring supply chain integrity entails evaluating each segment critically.

Active Pharmaceutical Ingredient (API) Suppliers for DYRENIUM

Global API Manufacturers

The foundation of any pharmaceutical supply chain lies with API producers. Leading global API manufacturers with extensive regulatory approvals and capacity for high-purity production are typically engaged in supplying advanced therapies like DYRENIUM:

• Lonza: Based in Switzerland, Lonza is a key supplier for biotech APIs, offering custom synthesis and production under stringent quality controls. Their capacity aligns with the needs of specialty drugs, including biologics.

• Fujifilm Diosynth Biotechnologies: Known for their expertise in biologics and complex APIs, they serve as potential suppliers especially if DYRENIUM falls into this category.

• Samsung Biologics: A dominant player in biologics manufacturing, Samsung’s expansive capacity and global footprint make them a strategic partner for complex APIs.

• Roche (through its APIs branch): With robust capabilities in biologics and complex chemical synthesis, Roche’s API division supplies a wide array of high-purity compounds to global markets.

• WuXi AppTec: A preferred contract manufacturer (CMO) providing integrated API synthesis, process development, and clinical trial supply services.

Regional API Suppliers

Regional suppliers may serve specific markets requiring localized manufacturing to reduce supply delays and costs:

• HIKAL Limited (India): An established bulk API manufacturer catering to generic and specialized drugs. Their under-regulation quality systems make them a feasible local supplier in emerging markets.

• Lipogene (Egypt): Emerging as a regional provider for biotech APIs, potentially relevant for less sensitive supply chains.

Contract Manufacturing Organizations (CMOs) & Formulation Suppliers

Once the API is procured, formulation and final drug product manufacturing are critical steps. Leading CMOs involved in biologic or specialized drug formulations include:

• Samsung Biologics: Not only API production but also formulation and fill-finish capabilities.

• Catalent: A global leader in drug formulation, caps, and packaging, providing end-to-end solutions for pharmaceutical finished products.

• Vetter Pharma: Known for sterile injectables and complex biologic formulations.

• Recipharm: Offers formulation, filling, and lyophilization, especially relevant for biologics or sensitive formulations.

Raw Material and Ancillary Suppliers

To ensure stable supply and quality, manufacturers source excipients, stabilizers, and other raw materials from experienced vendors. Notable suppliers include:

• Ashland: Provides pharmaceutical excipients with compliance to regulatory standards.

• Dow Chemical: Supplies polymers and stabilizers used in drug formulations.

• Merck KGaA: Offers raw materials such as buffers and reagents critical for biologic stability.

Supply Chain Considerations

Regulatory Compliance and Quality Assurance

Suppliers must meet stringent regulatory standards—FDA approval, EMA compliance, and cGMP adherence are non-negotiable. Prior audits and validation processes ensure ongoing quality.

Supply Chain Security and Diversification

Dependence on single-source suppliers introduces risk. Diversified supplier portfolios mitigate disruptions stemming from geopolitical tensions, natural disasters, or pandemic-related constraints.

Pricing and Contractual Arrangements

Negotiated contracts should balance pricing with quality assurance, lead-time flexibility, and scalability. Long-term partnerships foster reliability.

Technological Capabilities

Suppliers capable of handling complex biologics or specialty formulations should be prioritized, supporting the stability, efficacy, and regulatory approval of DYRENIUM.

Market Dynamics and Strategic Partnerships

The evolution of the global pharmaceutical supply chain increasingly emphasizes strategic alliances with pharmaceutical CDMOs and biotech firms. For DYRENIUM, partnerships with top-tier suppliers such as Lonza, Samsung, or Catalent can ensure supply stability, quality, and compliance.

Furthermore, geographic diversification supports market expansion and can optimize logistics. For instance, sourcing from FDA-compliant US or European manufacturers versus emerging market suppliers requires balancing cost, regulatory overhead, and timelines.

Emerging Trends Affecting Supplier Selection

• Adoption of Digitalization and Blockchain: Enhances traceability and integrity across the supply chain.

• Increasing Focus on Sustainability: Suppliers adopting environmentally sustainable practices are gaining preference.

• Expanding Capacity for Biologics: As biologics grow in prominence, suppliers investing in advanced biomanufacturing will be more attractive.

Conclusion

The supply ecosystem for DYRENIUM hinges on a network of high-quality API manufacturers, formulation specialists, and raw material providers. Establishing partnerships with established global providers such as Lonza, Samsung Biologics, and Catalent can mitigate risks, ensure regulatory compliance, and support scalability. Strategic diversification, due diligence, and technological alignment underpin a resilient supply chain capable of meeting market demands.

---

Key Takeaways

• Reliable sourcing for DYRENIUM requires engaging with established API manufacturers like Lonza, Samsung Biologics, and WuXi AppTec.

• Formulation and finishing stages benefit from partnerships with CMOs such as Catalent and Vetter Pharma, ensuring quality and compliance.

• Diversification across different geographic regions and suppliers minimizes supply chain risks.

• Prioritizing suppliers with advanced biologic manufacturing capabilities and digital supply chain solutions enhances stability and transparency.

• Continuous monitoring of market trends, regulatory standards, and technological innovations is essential for maintaining an optimized supply chain.

---

FAQs

1. What criteria should I consider when selecting suppliers for DYRENIUM?
Suppliers must demonstrate compliance with cGMP standards, possess robust quality assurance systems, have sufficient manufacturing capacity, and provide supply chain transparency. Regulatory track record and technological capabilities relevant to DYRENIUM’s formulation are also critical.

2. Are there regional differences in sourcing DYRENIUM’s raw materials?
Yes. US and European suppliers typically face stricter regulatory scrutiny but may involve higher costs. Emerging markets like India and Egypt offer cost advantages but require rigorous due diligence to meet quality standards.

3. How can supply chain risks for DYRENIUM be mitigated?
Diversification across multiple suppliers and regions, establishing strategic long-term partnerships, and maintaining safety stock levels are effective risk mitigation strategies. Incorporating digital tracking and real-time inventory management enhances supply chain resilience.

4. What role do CMOs play in the supply chain for DYRENIUM?
CMOs are integral to formulation, fill-finish, and packaging processes, especially for biologics or complex drugs, enabling scalability and compliance. Their expertise can reduce time-to-market and ensure consistent product quality.

5. How might future technological developments impact suppliers for DYRENIUM?
Adoption of biomanufacturing automation, process intensification, and digital supply chain solutions will influence supplier capabilities. Suppliers investing in these areas will be positioned as preferred partners for innovative drugs like DYRENIUM.

---

Sources:

[1] PharmaTrace. (2022). Global API Manufacturers List.
[2] CPhI. (2023). Contract Manufacturing and Sourcing Trends.
[3] ISPE. (2021). Industry Good Practice Guidelines for Biologics Manufacturing.
[4] Deloitte. (2022). Supply Chain Resilience in Pharma.
[5] FDA. (2023). Pharmaceutical Quality Standards and Regulations.